Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 3/20 | 0.39 |
| ▸ | RARB | P10826 | 3/20 | 0.39 |
| ▸ | RARG | P13631 | 3/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804494 | 0.94 | RARB (0.41) | RARARARBRARGLTB4RLTB4R2 | |
| SCHEMBL19804377 | 0.93 | EGFR (0.39) | RARARARBRARGLTB4RLTB4R2 | |
| SCHEMBL19804285 | 0.92 | SLC6A9 (0.40) | LTB4RLTB4R2EGFRSLC6A9PDE4A | |
| SCHEMBL19804533 | 0.91 | RARB (0.44) | RARARARBRARGLTB4RLTB4R2 | |
| SCHEMBL19804467 | 0.91 | RARA (0.36) | RARARARBRARGLTB4RLTB4R2 | |
| SCHEMBL19804288 | 0.90 | EGFR (0.38) | RARARARBRARGLTB4RLTB4R2 | |
| SCHEMBL19804415 | 0.90 | LTB4R (0.36) | RARARARBRARGLTB4RLTB4R2 | |
| SCHEMBL19804114 | 0.89 | LTB4R (0.37) | RARARARBRARGLTB4RLTB4R2 | |
| SCHEMBL19804308 | 0.89 | ALOX5AP (0.40) | LTB4RLTB4R2EGFRSLC6A9PDE4A | |
| SCHEMBL19804042 | 0.89 | RARA (0.36) | RARARARBRARGEGFRSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | RARA 3585/4885RARB 3517/4885RARG 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.